RT Journal Article
SR Electronic
T1 Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients
JF RMD Open
JO RMD Open
FD EULAR
SP e002693
DO 10.1136/rmdopen-2022-002693
VO 8
IS 2
A1 José Luis Martín-Varillas
A1 Lara Sanchez-Bilbao
A1 Vanesa Calvo-Río
A1 Alfredo Adán
A1 Inés Hernanz
A1 Adela Gallego-Flores
A1 Emma Beltran-Catalan
A1 Sonia Castro-Oreiro
A1 Patricia Fanlo
A1 Alvaro Garcia Martos
A1 Ignacio Torre
A1 Miguel Cordero-Coma
A1 Juan Ramon De Dios
A1 Ángel García-Aparicio
A1 Marisa Hernández-Garfella
A1 Amalia Sánchez-Andrade
A1 Andrea García-Valle
A1 Olga Maiz
A1 Roberto Miguélez
A1 Sergio Rodríguez-Montero
A1 Ana Urruticoechea
A1 Raúl Veroz
A1 Arantxa Conesa
A1 Cristina Fernández-Carballido
A1 Vega Jovaní
A1 Jose J Mondejar
A1 Olga Martínez González
A1 Patricia Moya Alvarado
A1 Susana Romero-Yuste
A1 Paula Rubio-Muñoz
A1 Eva Peña-Sainz-Pardo
A1 Marta Garijo-Bufort
A1 Rosalía Demetrio-Pablo
A1 José L Hernández
A1 Ricardo Blanco
YR 2022
UL http://rmdopen.bmj.com/content/8/2/e002693.abstract
AB Objectives To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID).Methods Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year.Results We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet’s disease (n=10), psoriatic arthritis (n=8), Crohn’s disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1),Conclusions CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.No data are available.